What development phase is Levobupivacaine Hydrochloride 0.25 % Injectable Solution in?

Levobupivacaine Hydrochloride 0.25 % Injectable Solution is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Levobupivacaine Hydrochloride 0.25 % Injectable Solution

Algemeen Ziekenhuis Maria Middelares · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Levobupivacaine Hydrochloride 0.25 % Injectable Solution
Also known as	IPP-PSP block, Intervention group
Sponsor	Algemeen Ziekenhuis Maria Middelares
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Interpectoral-pectoserratus Plane Block for Minimally Invasive Aortic Valve Replacement Via Right Anterior Minithoracotomy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Levobupivacaine Hydrochloride 0.25 % Injectable Solution CI brief — competitive landscape report
Levobupivacaine Hydrochloride 0.25 % Injectable Solution updates RSS · CI watch RSS
Algemeen Ziekenhuis Maria Middelares portfolio CI